

- 18 -

Claims

1. A method to induce an antitumor immune response in a potential or actual prostate tumor-bearing subject which method comprises administering to said
5 subject a composition comprising an active ingredient selected from the group consisting of
at least one antigen overrepresented in the prostate gland or an immunologically effective portion thereof;
10 an expression system capable of generating *in situ* said antigen; and
an antiidiotypic antibody or fragment thereof which mimics said antigen.
2. The method of claim 1 wherein said antigen
15 in a protein or peptide.
3. The method of claim 2 wherein said protein or peptide is selected from the group consisting of PSA, PSMA, PAP and a fragment thereof.
4. The method of claim 1 wherein said subject
20 is afflicted with metastatic prostate cancer.
5. The method of claim 1 wherein said subject has been surgically treated to excise said tumor but is at risk for recurrence.

- 19 -

Sub
C1
6. The method of claim 1 wherein said subject is in a "neoadjuvant" setting prior to surgical excision of said prostate tumor.

Sub
C1
7. The method of claim 1 wherein said subject is a potential prostate tumor-bearing subject at risk for said tumor.

Sub
C1
8. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises as active ingredient an expression system capable of generating *in situ* an antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof.

9. The vaccine of claim 8 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP and a portion thereof.

Sub
C1
10. The vaccine of claim 8 wherein the antigen is encapsulated in a liposome or coupled to a liposome.

11. The vaccine of claim 10 wherein said liposomes contain an adjuvant or are precipitated with alum.

12. The vaccine of claim 8 which further includes at least one adjuvant capable of enhancing said antitumor immune response.

- 20 -

Sub
Cl

13. The vaccine of claim 12 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria; polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

- 10 14. The vaccine of claim 8 wherein said expression system consists essentially of DNA encoding said antigen or portion or wherein said expression system comprises a living expression vector.

Sub
Cl

- 15 15. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in subject which comprises as active ingredient an antiidiotypic antibody or fragment thereof which mimics an antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof.

- 20 16. The vaccine of claim 15 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP and a portion thereof.

Sub
Cl

- 25 17. The vaccine of claim 15 wherein the antigen is encapsulated in a liposome or coupled to a liposome.

- 21 -

Sub
C1

18. The vaccine of claim 17 wherein said liposomes contain an adjuvant or are precipitated with alum.

19. The vaccine of claim 15 which further includes at least one adjuvant capable of enhancing said antitumor immune response.

20. The vaccine of claim 19 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria; polysaccharides; saponins; detoxified endotoxin (DETOX); muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

Sub
C2

21. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises as active ingredient at least one antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof, wherein said active ingredient is encapsulated in or coupled to a liposome.

22. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises at least two active ingredients each selected from the group consisting of

- 22 -

an antigen overrepresented on the prostate gland
with respect to other tissues or an immunologically
effective portion thereof;

an expression system capable of generating in
situ said antigen or portion; and
an antiidiotypic antibody or fragment thereof
which mimics said antigen or portion.

23. The vaccine of claim 22 wherein said
antigen is selected from the group consisting of PSA,
PSMA, PAP and a portion thereof.

24. The vaccine of claim 22 wherein the antigen
is encapsulated in a liposome or coupled to a liposome.

25. The vaccine of claim 24 wherein said
liposomes contain an adjuvant or are precipitated with
alum.

26. The vaccine of claim 22 which further
includes at least one adjuvant capable of enhancing said
antitumor immune response.

27. The vaccine of claim 26 wherein said
adjuvant is selected from the group consisting of Freund's
complete adjuvant; alum; lipid A; monophosphoryl lipid A;
Bacillus Calmette-Guerin (BCG) or other bacteria;
polysaccharides; saponins; detoxified endotoxin (DETOX);
muramyl tripeptide or muramyl dipeptide or their
derivatives; SAF1; lymphokines; cytokines; colony

- 23 -

Sub C1
stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

Sub C1
28. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors which comprises as active ingredient at least one immunologically effective portion of an antigen overrepresented on the prostate gland with respect to other tissues said portion being less than the complete antigen.

10 29. The vaccine of claim 28 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP.

30. The vaccine of claim 28 wherein the portion is encapsulated in a liposome or coupled to a liposome.

Sub C1
15 31. The vaccine of claim 30 wherein said liposomes contain an adjuvant or are precipitated with alum.

20 32. The vaccine of claim 28 which further includes at least one adjuvant capable of enhancing said antitumor immune response.

25 33. The vaccine of claim 32 wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria; polysaccharides; saponins; detoxified endotoxin (DETOX);

- 24 -

Sub
C1

muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).

5
Sub
C1

34. A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises as active ingredient at least one antigen overrepresented on the prostate gland with respect to other tissues with the proviso that said antigen is other than human prostate specific antigen (PSA) produced in human cells.

Sub
C1

35. The vaccine of claim 34 wherein said antigen is PSA recombinantly produced in nonhuman cells and exhibits posttranslational modifications different from those of PSA produced in human cells.

Sub
C1

36. The vaccine of claim 34 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP and a portion thereof.

Sub
C1

37. The vaccine of claim 34 wherein the antigen is encapsulated in a liposome or coupled to a liposome.

38. The vaccine of claim 37 wherein said liposomes contain an adjuvant or are precipitated with alum.

- 25 -

Sub
cl

39. The vaccine of claim 34 which further includes at least one adjuvant capable of enhancing said antitumor immune response.

40. The vaccine of claim 39 wherein said
5 adjuvant is selected from the group consisting of Freund's complete adjuvant; alum; lipid A; monophosphoryl lipid A; *Bacillus Calmette-Guerin* (BCG) or other bacteria; polysaccharides; saponins; detoxified endotoxin (DETOX);
10 muramyl tripeptide or muramyl dipeptide or their derivatives; SAF1; lymphokines; cytokines; colony stimulating factors; nonionic block copolymers; and immune stimulating complexes (ISCOMS).